Skip to main content

Table 4 Subgroup analysis of the PSM cohort (n = 220)

From: Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage

 number of patientsOverall survivalDisease-free survival
5-year OS % (95% CI)HR(95% CI)p value*5-year DFS % (95% CI)HR(95% CI)p value*
S-1XELOXS-1XELOX
Sex
 Male15273 (63–84)78 (68–90)0.63 (0.32–1.27)0.19666 (56–78)77 (67–88)0.60 (0.32–1.14)0.117
 Female6871 (57–89)76 (59–97)0.93 (0.35–2.48)0.89064 (49–83)68 (49–94)0.75 (0.32–1.77)0.507
Age (years)
  < 6513878 (68–88)87 (79–96)0.66 (0.29–1.50)0.31671 (61–83)77 (67–90)0.73 (0.36–1.44)0.361
  ≥ 658262 (48–80)64 (48–85)0.69 (0.32–1.51)0.35856 (42–74)69 (55–87)0.55 (0.261–1.18)0.125
Stage (AJCC 7th)
 IIA7100 (100–100)100 (100–100)NANA100 (100–100)100 (100–100)NANA
 IIB4089 (64–97)92 (57–99)0.67 (0.06–7.48)0.74785 (61–95)92 (54–99)0.38(0.04–3.68)0.405
 IIIA5489 (70–96)75 (33–93)1.56 (0.31–7.96)0.59385 (66–94)77 (53–90)1.58(0.43–5.76)0.487
 IIIB6778 (65–94)72 (55–94)1.35 (0.50–3.69)0.55466 (51–85)74 (60–92)0.84 (0.34–2.04)0.697
 IIIC5227 (10–46)68 (51–90)0.32 (0.14–0.76)0.00922 (8–41)57 (39–84)0.32 (0.15–0.70)0.004
 All II4790 (78–100)94 (83–100)0.58 (0.05–6.40)0.65587(74–100)93 (82–100)0.35 (0.04–3.34)0.360
 All III17367 (58–78)73 (62–86)0.73 (0.40–1.31)0.28560 (50–71)69 (59–81)0.67 (0.40–1.13)0.133
N stage
 N018100 (100–100)100 (100–100)NANA100 (100–100)100 (100–100)NANA
 N13393 (59–99)81 (52–94)3.40 (0.35–32.86)0.29087 (56–96)80 (50–93)1.81(0.30–10.96)0.519
 N27586 (71–94)77 (42–92)1.40 (0.36–5.41)0.62382 (65–91)78 (57–90)1.18(0.42–3.34)0.757
 N39447 (34–65)71 (58–86)0.45 (0.23–0.87)0.01938 (26–55)66 (52–82)0.40 (0.21–0.75)0.004
T stage
 T17100 (100–100)100 (100–100)NANA75 (13–96)100 (100–100)0.42(0.00–41.43)0.712
 T21686 (33–98)86 (33–98)0.87 (0.05–13.85)0.91988 (39–98)86 (33–98)0.93(0.06–14.83)0.957
 T38080 (68–93)81 (66–99)0.75 (0.25–2.23)0.60474 (62–90)80 (67–95)0.78 (0.30–2.05)0.617
 T4a,b11764 (52–78)72 (59–88)0.69 (0.35–1.37)0.29056 (42–68)67 (50–79)0.61 (0.33–1.14)0.121
LNR group
 LNR 018100 (100–100)100 (100–100)NANA100 (100–100)100 (100–100)NANA
 LNR 17194 (78–98)86 (61–96)3.01 (0.55–16.59)0.20588 (72–95)85 (65–94)1.43(0.41–4.99)0.579
 LNR 28074 (57–85)72 (50–86)0.84 (0.34–2.10)0.70566 (49–79)74 (56–85)0.73(0.32–1.68)0.464
 LNR 35126 (12–55)67 (50–89)0.28 (0.11–0.71)0.02020 (9–47)54 (35–82)0.29 (0.13–0.65)0.004
  1. *The hazard ratio of the XELOX group using the S-1 group as the reference and the 95% CIs were calculated using Cox’s proportional hazards model
  2. †NA = not evaluable
  3. Abbreviations: CI confidence interval, HR hazard ratio. Significant values are in boldface type